Turn off MathJax
Article Contents
Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao. Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia[J]. Blood&Genomics. doi: 10.46701/BG.2023022022039
Citation: Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao. Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia[J]. Blood&Genomics. doi: 10.46701/BG.2023022022039

Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia

doi: 10.46701/BG.2023022022039
More Information
  • Corresponding author: Xi Zhang and Li Gao, Medical Center of Hematology, Xinqiao Hospital; State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, No.183 Xinqiao Main Street, Shapingba District, Chongqing 400037, China. E-mails: zhangxxi@sina.com and gaotiantiantiger@163.com
  • Received Date: 2022-12-24
  • Rev Recd Date: 2023-03-11
  • Accepted Date: 2023-05-24
  • Available Online: 2023-08-09
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially for refractory acute lymphoblastic leukemia. However, they are relatively expensive, limiting their widespread use. For patients lacking matched sibling donors, haploidentical donors are an option. This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT (n=68) or human leukocyte antigen (HLA)-matched HSCT (n=51). The 2-year overall survival (OS) and leukemia-free survival (LFS) in the haploidentical HSCT group were similar to those in the HLA-matched HSCT group (77.6% vs. 88.6%, P=0.076; 55.6% vs. 52.9%, P=0.497). The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively (P=0.526). Analysis of the 3-year cumulative recurrence rate suggested no significant difference between the haploidentical HSCT group and HLA-matched HSCT group (cumulative incidence, 32.7% vs. 31.2%, P=0.801). The cumulative incidence of acute GVHD, non-relapse mortality (NRM), and graft-versus-host relapse-free survival (GRFS) were similar in both groups. There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population.


  • These authors contributed equally to this work.
  • loading
  • [1]
    Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy[J]. Curr Opin Pediatr, 2020, 32(1): 57−66. doi: 10.1097/MOP.0000000000000855
    O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(7): 926−957. doi: 10.6004/jnccn.2017.0116
    Brown P, Inaba H, Annesley C, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(1): 81−112. doi: 10.6004/jnccn.2020.0001
    Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation[J]. Br J Haematol, 2017, 179(4): 598−605. doi: 10.1111/bjh.14923
    Liu J, Zhang X, Zhong JF, et al. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Immunotherapy, 2017, 9(13): 1115−1125. doi: 10.2217/imt-2017-0072
    Wang X, Huang R, Zhang X, et al. Current status and prospects of hematopoietic stem cell transplantation in China[J]. Chin Med J (Engl), 2022, 135(12): 1394−1403. doi: 10.1097/CM9.0000000000002235
    Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China[J]. J Hematol Oncol, 2015, 8: 90. doi: 10.1186/s13045-015-0186-5
    Wang Y, Chen H, Chen J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China[J]. Cancer Lett, 2018, 438: 63−75. doi: 10.1016/j.canlet.2018.08.030
    Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389−401.e1. doi: 10.1016/j.bbmt.2014.12.001
    Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission[J]. Bone Marrow Transplant, 2016, 51(4): 610−611. doi: 10.1038/bmt.2015.305
    Zheng FM, Zhang X, Li CF, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study[J]. Cancer Commun (Lond), 2020, 40(2–3): 93−104. doi: 10.1002/cac2.12014
    Jia Y, Li W, Wang L, et al. Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, and -DQB1 in Chinese patients with hematological diseases[J]. Blood Genom, 2018, 2(1): 27−37. doi: 10.46701/APJBG.2018012017064
    Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients[J]. Bone Marrow Transplant, 2008, 41(2): 207−214. doi: 10.1038/sj.bmt.1705963
    Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease[J]. Blood, 2012, 120(22): 4285−4291. doi: 10.1182/blood-2012-07-438408
    Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma[J]. Hum Immunol, 1990, 29(2): 79−91. doi: 10.1016/0198-8859(90)90071-v
    Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings[J]. N Engl J Med, 1985, 313(13): 765−771. doi: 10.1056/NEJM198509263131301
    Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders[J]. Blood, 2014, 124(5): 822−826. doi: 10.1182/blood-2014-03-563817
    Xu LP, Liu KY, Liu DH, et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis[J]. Bone Marrow Transplant, 2010, 45(6): 985−992. doi: 10.1038/bmt.2009.311
    Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(11): 1863−1869. doi: 10.1016/j.bbmt.2015.07.032
    Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation[J]. Blood, 2001, 98(12): 3221−3227. doi: 10.1182/blood.v98.12.3221
    Li Y, Chang Y, Xu L, et al. Negative association of donor age with CD34(+) cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests[J]. Chin Med J (Engl), 2014, 127(20): 3597–3601.
    Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. Blood, 2014, 124(6): 843−850. doi: 10.1182/blood-2014-03-563130
    Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia[J]. Cell, 2012, 150(2): 264−278. doi: 10.1016/j.cell.2012.06.023
    Gooptu M, Antin JH. GVHD prophylaxis 2020[J]. Front Immunol, 2021, 12: 605726. doi: 10.3389/fimmu.2021.605726
    Gao L, Liu J, Zhang Y, et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation[J]. Leuk Res, 2017, 57: 27−36. doi: 10.1016/j.leukres.2017.02.006
    Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro[J]. Blood, 2008, 111(7): 3675−3683. doi: 10.1182/blood-2008-01-130146
    Zhou X, Lu X, Tang L, et al. Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies[J]. Chin J Hematol (in Chinese), 2020, 41(7): 557−563. doi: 10.3760/cma.j.issn.0253-2727.2020.07.005
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective[J]. Biol Blood Marrow Transplant, 2009, 15(10): 1143−1238. doi: 10.1016/j.bbmt.2009.06.019
    Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation[J]. Curr Oncol, 2019, 26(3): 187−191. doi: 10.3747/co.26.5033
    Mo XD, Tang BL, Zhang XH, et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia[J]. Int J Cancer, 2016, 139(9): 2106−2115. doi: 10.1002/ijc.30249
    Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial[J]. J Clin Oncol, 2015, 33(11): 1265−1274. doi: 10.1200/JCO.2014.58.9747
    Kawamura K, Nakasone H, Kurosawa S, et al. Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1521−1526. doi: 10.1016/j.bbmt.2018.02.004
    Sakaguchi H, Watanabe N, Matsumoto K, et al. Comparison of donor sources in hematopoietic stem cell transplantation for childhood acute leukemia: a nationwide retrospective study[J]. Biol Blood Marrow Transplant, 2016, 22(12): 2226−2234. doi: 10.1016/j.bbmt.2016.09.020
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Article Metrics

    Article views (102) PDF downloads(3) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint